论文部分内容阅读
Introduction: Better prognostic and predictive tools are necessary for personalized treatment decisions in lymph node-negative, estrogen receptor-positive breast cancer patients.The 21-gene recurrence score (RS) assay was developed to predict the likelihood of distant recurrence and chemotherapy benefit in women with estrogen receptor-positive, lymph node-negative breast cancer treated with adjuvant tamoxifen.